<DOC>
	<DOC>NCT02860845</DOC>
	<brief_summary>The purpose of this study is to determine whether a formula of boric acid and probiotics for vaginal application is effective in the treatment of symptomatic episodes of vulvovaginitis in comparison to pharmacological reference controls (depending on the suspected diagnosis).</brief_summary>
	<brief_title>Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections</brief_title>
	<detailed_description>Multicentre, Open, Prospective, Randomized, Controlled. Women with suspected vaginal infection will be randomized and distributed into two groups (control or boric acid + probiotics). Follow-up will last for three months and consists in 3 visits and a telephone interview.</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<criteria>Age over 18 years and agreement to participate by signing the consent form. Women with clinical manifestations of acute infectious vulvovaginitis (burning, pruritus, erythema, oedema, and abnormal vaginal discharge). Clinical findings compatible with Chlamydia trachomatis, Neisseria gonorrhoeae or Trichomonas vaginalis infection. Use of antifungal, antibiotic or probiotic medication within last 2 weeks prior to the study. Patients receiving other treatment (drug, probiotics or vitamin supplements) that can significantly interfere with study evaluations during the 3 months of followup. Pregnant or high risk for pregnancy.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>